Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 hospitalized patients transfused with investigational convalescent plasma as part of the U.S. Food and Drug Administration’s national Expanded Access Program (EAP) for COVID-19.

The safety report assessed the seven days following transfusion for hospitalized patients between April 3 and June 11, 2020, who were deemed at risk of progressing to a severe or life-threatening condition. This update provides safety data from 20,000 patients, including the initial 5,000 and subsequent 15,000 transfused patients. Data from the first 5,000 transfused patients were reported previously. The safety update highlights include: